RECOVERY Collaborative Group 2023, ' Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 401, no. 10387, pp. 1499-1507 . https://doi.org/10.1016/S0140-6736(23)00510-X
Eurosurveillance Romaní Vidal, A, Vaughan, A, Innocenti, F, Colombe, S, Nerlander, L, Rachwal, N, Ciancio, B C, Mougkou, A, Carvalho, C, Delgado, E, Mook, P, de Muylder, G, Peeters, M, Tenev, T, Golkocheva-Markova, E, Vorobieva Solholm Jensen, V, Koch, A, Figoni, J, Brouard, C, Nikolopoulou, G, Zisouli, A, Broderick, A, Goldberg, L, Rich, R, Hecht Sagie, L, Tosti, M E, Suligoi, B, Joosten, R, Pijnacker, R, Fjeldheim, I, Heen, E, Stępień, M, Polański, P, Tato Marinho, R, Vieira Martins, J, Varela, C, Avellón, A, Andersson, E, Jansson Mörk, M, Mandal, S, Watson, C, Coughlan, L, Chand, M, Neill, C, Bradley, D T, Li, K, O’Leary, M, McInnes, N, Williams, C J, Gjini, A, Duffell, E & Pebody, R 2022, ' Hepatitis of unknown aetiology in children – epidemiological overview of cases reported in Europe, 1 January to 16 June 2022 ', EUROSURVEILLANCE, vol. 27, no. 31 . https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200483
Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5
International Journal of Environmental Research and Public Health International Journal of Environmental Research and Public Health; Volume 13; Issue 4; Pages: 359 International Journal of Environmental Research and Public Health, Vol 13, Iss 4, p 359 (2016)